XEMA Co. Ltd. (formerly Xema-Medica) is a biotechnology and health care company established in Moscow in February 1993. The company has focused its research on various areas including biochemistry and immunology of human and veterinary tumor markers, immunochemistry of food antigens, study of fungal antigens, and development of immunoassays. Since 1997, XEMA has entered the market of in vitro diagnostic reagents, offering a broad panel of EIA kits for various medical and veterinary purposes. In addition, the company has developed kits for research use in medicine and food control. XEMA exports its production to several countries including C.I.S. countries, Germany, Italy, Belgium, China, Israel, Turkey, Iran, Malaysia, and Indonesia, with annual sales reaching around 7 million USD in 2010. This extensive research and product development showcase XEMA's commitment to innovation and its potential for growth in the biotechnology and healthcare industries. With its established presence in international markets and a diverse range of product offerings, XEMA presents an intriguing opportunity for potential venture capital investment. Its proven track record of addressing diverse market needs and its expansion into international markets position XEMA as a promising investment prospect within the biotechnology and healthcare sectors.
There is no investment information
No recent news or press coverage available for XEMA.
We care about your data, and we'd love to use cookies make your experience better.
